Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Soligenix announces progress in pre-clinical development of COVID-19 vaccine » 07:05
03/04/21
03/04
07:05
03/04/21
07:05
SNGX

Soligenix

$1.60 /

-0.045 (-2.74%)

Soligenix announced…

Soligenix announced publication of pre-clinical immunogenicity studies for CiVax (heat stable COVID-19 vaccine program) demonstrating rapid-onset, broad-spectrum, neutralizing antibody and cell-mediated immunity is confirmed using full-length Spike protein antigens. The article titled, "Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice," has been posted as an accelerated preprint on bioRxiv. This work will continue under a $1.5M Small Business Innovation Research grant awarded to Soligenix in December 2020.

ShowHide Related Items >><<
SNGX Soligenix
$1.60 /

-0.045 (-2.74%)

SNGX Soligenix
$1.60 /

-0.045 (-2.74%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.60 /

-0.045 (-2.74%)

Over a week ago
Hot Stocks
Soligenix CEO sees capital and cush runway sufficient through 2022 » 07:14
02/24/21
02/24
07:14
02/24/21
07:14
SNGX

Soligenix

$1.73 /

-0.03 (-1.71%)

Expects peak annual net…

Expects peak annual net sales of SGX301 in the U.S. to exceed $90M, with the total addressable worldwide market estimated at approximately $250M annually. Expects to begin rolling NDA submission for SGX301 in Q2. Expects total U:S. revenues during 10-year forecast period to be above $700M.

ShowHide Related Items >><<
SNGX Soligenix
$1.73 /

-0.03 (-1.71%)

SNGX Soligenix
$1.73 /

-0.03 (-1.71%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.73 /

-0.03 (-1.71%)

Over a month ago
Hot Stocks
Soligenix receives Hong Kong patent for therapeutic use of synthetic hypericin » 07:03
02/01/21
02/01
07:03
02/01/21
07:03
SNGX

Soligenix

$1.54 /

-0.02 (-1.28%)

Soligenix announced that…

Soligenix announced that the Hong Kong Registrar of Patents has granted a patent for the application titled "Formulations and Methods of Treatment of Skin Conditions", No. 16102842.8, published on January 29 under Publication No. 1214771 B. The granted claims are directed to the therapeutic use of synthetic hypericin in the treatment of cutaneous T-cell lymphoma, or CTCL, similar to those granted in Europe in 2020. Synthetic hypericin is the active pharmaceutical ingredient in SGX301. This new patent is the first granted in Hong Kong and expands on Soligenix's comprehensive patent estate, which includes protection on the composition of the purified synthetic hypericin, methods of synthesis and therapeutic methods of use in both CTCL and psoriasis, and is being pursued worldwide.

ShowHide Related Items >><<
SNGX Soligenix
$1.54 /

-0.02 (-1.28%)

SNGX Soligenix
$1.54 /

-0.02 (-1.28%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.54 /

-0.02 (-1.28%)

SNGX Soligenix
$1.54 /

-0.02 (-1.28%)

Conference/Events
Soligenix to host business news update conference call » 14:25
01/26/21
01/26
14:25
01/26/21
14:25
SNGX

Soligenix

$1.80 /

-0.04 (-2.17%)

Management discusses the…

Management discusses the U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
SNGX Soligenix
$1.80 /

-0.04 (-2.17%)

SNGX Soligenix
$1.80 /

-0.04 (-2.17%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.80 /

-0.04 (-2.17%)

SNGX Soligenix
$1.80 /

-0.04 (-2.17%)

Conference/Events
Soligenix to hold a conference call » 14:15
01/26/21
01/26
14:15
01/26/21
14:15
SNGX

Soligenix

$1.81 /

-0.035 (-1.90%)

Management discusses U.S.…

Management discusses U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
SNGX Soligenix
$1.81 /

-0.035 (-1.90%)

SNGX Soligenix
$1.81 /

-0.035 (-1.90%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.81 /

-0.035 (-1.90%)

SNGX Soligenix
$1.81 /

-0.035 (-1.90%)

Conference/Events
Soligenix to hold a conference call » 10:44
01/26/21
01/26
10:44
01/26/21
10:44
SNGX

Soligenix

$1.74 /

-0.1 (-5.43%)

Management discusses U.S.…

Management discusses U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
SNGX Soligenix
$1.74 /

-0.1 (-5.43%)

SNGX Soligenix
$1.74 /

-0.1 (-5.43%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.74 /

-0.1 (-5.43%)

SNGX Soligenix
$1.74 /

-0.1 (-5.43%)

Conference/Events
Soligenix to host business news update conference call » 04:55
01/26/21
01/26
04:55
01/26/21
04:55
SNGX

Soligenix

$1.84 /

+0.14 (+8.24%)

Management discusses the…

Management discusses the U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
SNGX Soligenix
$1.84 /

+0.14 (+8.24%)

SNGX Soligenix
$1.84 /

+0.14 (+8.24%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.84 /

+0.14 (+8.24%)

SNGX Soligenix
$1.84 /

+0.14 (+8.24%)

Conference/Events
Soligenix to host business news update conference call » 16:14
01/19/21
01/19
16:14
01/19/21
16:14
SNGX

Soligenix

$1.69 /

+0.28 (+19.86%)

Management discusses the…

Management discusses the U.S. commercial planning for SGX301 in the treatment of Cutaneous T-Cell Lymphoma (CTCL) on a conference call to be held on January 26 at 2:30 pm. Webcast Link

ShowHide Related Items >><<
SNGX Soligenix
$1.69 /

+0.28 (+19.86%)

SNGX Soligenix
$1.69 /

+0.28 (+19.86%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.69 /

+0.28 (+19.86%)

SNGX Soligenix
$1.69 /

+0.28 (+19.86%)

Syndicate
Soligenix files to sell 4.88M shares of common stock for holders  16:32
01/15/21
01/15
16:32
01/15/21
16:32
SNGX

Soligenix

$1.41 /

-0.03 (-2.08%)

 
ShowHide Related Items >><<
SNGX Soligenix
$1.41 /

-0.03 (-2.08%)

SNGX Soligenix
$1.41 /

-0.03 (-2.08%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.41 /

-0.03 (-2.08%)

SNGX Soligenix
$1.41 /

-0.03 (-2.08%)

Hot Stocks
Soligenix, Daavlin enter strategic partnership for lymphoma treatment device » 07:06
01/07/21
01/07
07:06
01/07/21
07:06
SNGX

Soligenix

$1.31 /

-0.015 (-1.14%)

Soligenix has signed an…

Soligenix has signed an exclusive Supply, Distribution and Services Agreement with Daavlin. Securing long-term supply and distribution of a commercially ready light device is an integral component of the regulatory and commercial strategy for SGX301 for the treatment of cutaneous T-cell lymphoma. The company's corporate headquarters and manufacturing plant are located in Bryan, Ohio. Daavlin will exclusively manufacture the proprietary light device for use with SGX301 for the treatment of CTCL. Upon approval of SGX301 by the FDA, Soligenix will promote SGX301 and the companion light device, and facilitate the direct purchase of the device from Daavlin; and Daavlin will exclusively distribute and sell the SGX301 light device to Soligenix, physicians and patients.

ShowHide Related Items >><<
SNGX Soligenix
$1.31 /

-0.015 (-1.14%)

SNGX Soligenix
$1.31 /

-0.015 (-1.14%)

12/23/20 Alliance Global Partners
Soligenix price target lowered to $5.75 from $7.25 at Alliance Global Partners
12/04/20 B. Riley Securities
B. Riley sees 100% upside in Soligenix, starts with Buy rating
12/04/20 B. Riley Securities
Soligenix initiated with a Buy at B. Riley Securities
07/28/20 Dawson James
Soligenix downgraded to Neutral from Buy at Dawson James
SNGX Soligenix
$1.31 /

-0.015 (-1.14%)

SNGX Soligenix
$1.31 /

-0.015 (-1.14%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.